Fludarabine-based combination therapies for Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 67-70

  Tedeschi, Alessandra ^a   Alamos, Sara Miqueleiz ^a   Ricci, Francesca ^a   Greco, Antonino ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Immunosuppression; Myelodysplastic syndrome; Nucleoside analogues; Richter's transformation; Waldenstr m

Indexed keywords

CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; HUMAN; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; VIDARABINE; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649556693     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.017     Document Type: Article

References (31)

1. Kantarjian HM, Alexanian R, Koller CA, et al. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75:1928-31.
2. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Am J Med 1993; 95:49-52.
3. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia. Eur J Haematol 1995; 54:120-3.
4. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldeström's macroglobulinemia: a report of 71 cases. Group Coopératif Macroglobulinémie. J Clin Oncol 1998; 16:2060-4.
5. Leblond V, Lévy V, Maloisel F, et al. Multicenter randomized comparative trial of fludarabine and the combination of cyclophosphamide- doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first remission or in primary refractory disease. Blood 2001; 98:2640-4.
6. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström Macroglobulinemia: results of United States intergroup trial (South West Oncology Group S9003). Blood 2001; 98:41-8.
7. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicentre phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma. Waldenström's macroglobulinemia and mantle-cell lymphoma. J Clin Oncol 1999; 17:546-53.
8. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 2000; 79:556-9.
9. Yamauchi T, Nowak BJ, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7:3580-9.
10. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44:993-6.
11. Tam CS, Wolf MM, Westerman D, et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2005; 6:136-9.
12. Tamburini J, Lévy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia 2005; 19:1831-4.
13. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107:3442-6.
14. Treon SP, Branagan A, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2008. Epub ahead of print.
15. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-86.
16. Tam CS, Wolf M, Prince MH, et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006; 106:2412-20.
17. Vargaftig J, Pegourie-Bandelier B, Mahe B, et al. Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenström's macroglobulinemia: results in 25 patients. Haematologica 2007; 92(suppl 2):227 (Abstract PO-1226).
18. Tedeschi A, Miqueleiz S, Ricci F, et al. Fludarabine, cyclophosphamide and rituximab in Waldenström's macroglobulinemia: an effective regimen requiring new category response criteria and a delayed assessment results. Blood 2007; 110:388a (Abstract 1290).
19. Del Giudice I, Matutes E, Osujy N, et al. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. Haematologica 2005; 90:268-70.
20. Polizzotto MN, Tam CS, Milner A, et al. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 2006; 107:773-80.
21. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695-700.
22. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4:371-5.
23. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064-71.
24. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with Rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood 2003; 101:6-14.
25. Michallet M, Thiébaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL) a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working party (CLWP). Br J Haematol 2000; 108:595-601
26. Montillo M, Tedeschi A, Rossi V, et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia 2004; 18:57-62.
27. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008; 111:1820-6.
28. Stone MJ, Merlini GP, Pascual V. Autoantibody activity in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 225-9.
29. Aslan DL, Peterson BA, Long-Tsai M, et al. Early onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia. Transfusion 2006; 46:90-4.
30. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodisplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogues. J Clin Oncol 2009; 27:250-5.
31. Dimopoulos MA, Gertz M, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2008; 27:120-6.